11 Facts About CSL Limited


CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions.

FactSnippet No. 1,225,716

CSL Limited was founded in 1916 as the Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture.

FactSnippet No. 1,225,717

Under the first director, William Penfold, CSL Limited commenced operation in the vacant Walter and Eliza Hall Institute building at the Royal Melbourne Hospital in 1918, before moving to its purpose-built Parkville premises in the following year.

FactSnippet No. 1,225,718

In 1928, CSL Limited became involved in antivenene manufacture in conjunction with the snake venom research undertaken by Charles Kellaway at the Hall Institute.

FactSnippet No. 1,225,719

CSL Limited completed an initial public offering in June 1994 at A$2.

FactSnippet No. 1,225,720

In 2000, CSL Limited doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG.

FactSnippet No. 1,225,721

CSL Limited was the second Australian public company to have reached a share price of over $100 per share.

FactSnippet No. 1,225,722

In November 2015, BioCSL Limited rebranded the combined business with Novartis Influenza Vaccines as Seqirus [Sek-eer-us] creating the world's second largest influenza vaccine company.

FactSnippet No. 1,225,723

In June 2020 CSL Limited announced it would exercise its right to acquire Vitaeris.

FactSnippet No. 1,225,724

CSL Limited provided vaccines for customers in Singapore and the US.

FactSnippet No. 1,225,725

On 7 September 2020, CSL Limited signed agreements with the Australian government to supply the University of Queensland vaccine and to manufacture the Oxford University vaccine, which would yield nearly 85 million doses for Australians.

FactSnippet No. 1,225,726